Evicenter
P&T meetings

Imsidolimab

Generalized pustular psoriasis

Regulatory submission
BLA submitted December 2025
Last updated
85 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

TNF inhibitors

2 evidence topics · 1 source

Expert recommendations: position of cytokine-targeted biologics other than IL-36 inhibitors

“Systemic Biologics That Target the Predominant Cytokines in Plaque Psoriasis Should Be Considered Second-Line Therapy for the Treatment of GPP” (opens the source at this quote in a new tab)

TNF inhibitors described in the treatment recommendations

“adalimumab, infliximab, and certolizumab pegol” (opens the source at this quote in a new tab)